Sanofi's Rare Disease Drug Tolebrutinib Fails to Meet Primary Endpoint in Phase III Trial for Primary Progressive Multiple Sclerosis

On December 15, Sanofi announced the latest progress of its drug tolebrutinib in the treatment of primary progressive multiple sclerosis (PPMS).

Tolebrutinib is an investigational, oral, brain-penetrant BTK inhibitor. The drug’s mechanism of action addresses the underlying pathology of progressive MS by targeting inflammatory processes that drive neurodegeneration and the accumulation of disability.

The results of the Phase III PERSEUS clinical trial (NCT04458051) showed that tolebrutinib failed to meet its primary endpoint, as it did not demonstrate superiority over placebo in delaying the time to 6-month confirmed composite disability progression (cCDP).

In light of these results, Sanofi is unlikely to pursue regulatory approval for tolebrutinib in PPMS.

Houman Ashrafian, Executive Vice President and Head of Research and Development at Sanofi, expressed disappointment with the results but stated his belief that these data will help enhance understanding of the underlying disease biology of multiple sclerosis. He extended his deepest gratitude to the participants in the study, their families, and healthcare professionals. Sanofi’s commitment to the multiple sclerosis community remains unwavering, and the company will continue to strive for new advancements that address existing unmet needs. Despite the setback in the PPMS trial, Sanofi remains confident in the value that tolebrutinib can bring to individuals with non-relapsing secondary progressive multiple sclerosis (nrSPMS).